Project Grant W81XWH2211074

Federal Cooperative Agreement Summary STAT-CAT Clinical Trial Award Brigham & Women's Hospital, Inc. received a $4.58 million Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) randomized clinical trial. Awarded on August 1, 2025, with performance through July 31, 2026, this initiative will enroll up to 4,000...

Federal Cooperative Agreement Summary Brigham & Women's Hospital Inc. received a $1.72 million Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for July 31, 2032. This award funds the STAT-CAT (Statins to Prevent Cancer Associated Venous Thromboembolism) trial, a randomized clinical study designed to evaluate whether rosuvastatin 20 mg daily can...

Federal Project Grant Award Summary The University of Virginia received a $1.46 million Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded on April 14, 2026, with a three-year performance period concluding April 13, 2029. The project, titled "Preserving Lung Integrity and Harnessing Inflammation to Treat Vesicant-Induced Lung Injury," focuses on developing therapeutic approaches to...

This $3,757,391 Project Grant award from the U.S. Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the development of a field-use therapeutic for pulmonary injuries from trauma or chemical exposure. The awardee, Ceria Therapeutics Inc., is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The funding will enable Ceria Therapeutics to advance its...

Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $150,104 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for research on cardiovascular and respiratory responses to physical activity and heat stress in burn survivors. The award, dated March 2, 2026, with completion targeted for September 3, 2028, supports experimental research investigating whether...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Children's Research Institute a $3,051,981.02 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous L-citrulline for treating vaso-occlusive crisis (VOC) in sickle cell disease patients. The four-year research initiative, commencing May 1, 2025 and concluding April 30, 2029, aims to...

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

The University of Southern California received an $807,860 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 12, 2025, with completion by September 11, 2028. The grant supports the SUSTAIN (Stroke Volume-Based Fluid Resuscitation in Acute Pancreatitis) trial, a multi-center randomized controlled trial designed to optimize fluid therapy...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $2.39 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the SPARC Trial (The Effect of Specialty Care on Recovery from Cardiac Arrest). The award, effective September 1, 2025 through August 31, 2026, funds a randomized controlled trial designed to evaluate whether transfer to a specialty cardiac arrest center improves...

Grant Award Summary Northwestern University's Sponsored Research Division received a $773,538 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective April 1, 2026 through March 31, 2031. This award funds the NICE Trial (Nicotinamide Riboside to Improve Functioning in PAD), a Phase III multi-centered, double-blinded randomized clinical trial investigating the therapeutic efficacy of nicotinamide riboside (NR), a B3 vitamin precursor to...